Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces NIH Research Collaboration for Rare and Neglected Diseases

Concert Pharmaceuticals Announces NIH Research Collaboration for Rare and Neglected Diseases

November 15, 2011

Lexington, MA – Concert Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Agios Secures $78 Million in Oversubscribed Series C Financing

Agios Secures $78 Million in Oversubscribed Series C Financing

November 17, 2011

Cambridge, Mass. – Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced that is has secured $78 million in an oversubscribed Series C financing. The proceeds of this financing will be used to advance the company’s rapidly emerging portfolio of cancer metabolism therapeutics into the clinic and to expand research and development into inborn errors of metabolism (IEMs), a group of genetic disorders with high unmet medical need.
 

Celexion LLC

Celexion licensee BioAmber registers for IPO

Celexion licensee BioAmber registers for IPO

November 14, 2011

Today, BioAmber, a next generation chemicals company and licensee of Flagship portfolio company Celexion, announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock.

Theracrine Announces Publication Identifying Potential Novel Cancer Spread Target

Theracrine Announces Publication Identifying Potential Novel Cancer Spread Target

October 17, 2011

CAMBRIDGE, Mass. -- Theracrine, Inc., the first biopharmaceutical company focused on the discovery and development of novel therapeutics to treat cancer spread, today announced the publication of research from the lab of scientific founder Joan Massague, Ph.D. in Cancer Cell that elucidates the fundamental nature of cancer spread as well as the role of tumor-stromal interactions. The research specifically demonstrates the central role of VCAM-1 and VLA-4 in the survival and growth of metastatic breast cancer cells.

Novomer, Inc.

Novomer Wins ICIS Award for Innovation with Best Environmental Benefit

Novomer Wins ICIS Award for Innovation with Best Environmental Benefit

October 19, 2011

BOSTON, MA -- (Marketwire) - Novomer Inc., a sustainable materials company pioneering a family of high-performance plastics, polymers and other chemicals from renewable feedstocks such as carbon dioxide (CO2) and carbon monoxide (CO), today announced that it was selected for a prestigious 2011 ICIS Innovation Award. Lauded as the "Innovation with Best Environmental Benefit," the company's revolutionary technology was recognized for using CO2 as raw material to create high-performance polyols for coatings, adhesives, foams, composites and surfactant applications.

Selecta Biosciences, Inc.
BIND Therapeutics, Inc.

RUSNANO invests in Selecta Biosciences and BIND Biosciences to develop and commercialize vaccines and cancer drugs through expanded operations in Russia

RUSNANO invests in Selecta Biosciences and BIND Biosciences to develop and commercialize vaccines and cancer drugs through expanded operations in Russia

October 27, 2011

BIND and Selecta establish subsidiaries in Russia to access scientific and clinical expertise that will accelerate development of drugs and drug candidates.

BG Medicine, Inc.

BG Medicine, Inc. Announces Availability of Galectin-3 Testing Through Cleveland HeartLab, Inc.

BG Medicine, Inc. Announces Availability of Galectin-3 Testing Through Cleveland HeartLab, Inc.

October 27, 2011

WALTHAM, Mass. -- (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that Cleveland HeartLab, Inc. is now offering BGM Galectin-3TM testing services.

Alvine Pharmaceuticals, Inc.

Alvine Pharmaceuticals Presents Additional Efficacy Data From Phase 2a Trial of ALV003 in Celiac Disease Patients

Alvine Pharmaceuticals Presents Additional Efficacy Data From Phase 2a Trial of ALV003 in Celiac Disease Patients

October 24, 2011

SAN CARLOS, CA -- (Marketwire) -- Alvine Pharmaceuticals, Inc. today announced additional efficacy data from its Phase 2a clinical trial of ALV003. Results showed that oral ALV003, administered in the context of a gluten free diet (GFD), diminished gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The study findings were presented today in a late-breaking oral session at the 19th United European Gastroenterology Week (UEGW) in Stockholm.

T2 Biosystems, Inc.

T2 Biosystems Announces the Presentation of Data on Direct Detection with T2Candida

T2 Biosystems Announces the Presentation of Data on Direct Detection with T2Candida

October 21, 2011

Lexington, MA, October 21, 2011 – T2 Biosystems, a company developing direct detection products for superior diagnostics, today announced the presentation of data on its T2MR platform for detection of infectious diseases at the 49th Annual Meeting of the Infectious Disease Society of America (IDSA) in Boston, MA, October 20-23, 2011. Two independent research groups from Massachusetts General Hospital and University of Houston College of Pharmacy used the T2MR platform to analyze whole blood specimens from patients with 5 different types of Candida spp. infections.

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces CTP-499 Data Presentations at the American Society of Nephrology (ASN) Kidney Week Meeting

Concert Pharmaceuticals Announces CTP-499 Data Presentations at the American Society of Nephrology (ASN) Kidney Week Meeting

October 19, 2011

Lexington, MA – Concert Pharmaceuticals, Inc. today announced that three abstracts relating to CTP-499, its clinical candidate for the potential treatment of diabetic nephropathy, have been accepted for poster presentations at the American Society of Nephrology’s (ASN) Kidney Week 2011.  The annual meeting will be held November 8-13, 2011 in Philadelphia, PA.  Full abstracts can be viewed online at http://www.asn-online.org/education_and_meetings/kidneyweek/archives/.